Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Yutaka Ariyoshi"'
Autor:
Yutaka Ariyoshi, Koji Kakihata, Jun-ichi Tadokoro, Shuji Masatani, Masahiro Fukuoka, Yuh Sakata, Tomoo Shiozawa, Minoru Shimazaki, Fumie Yamaguchi
Publikováno v:
Japanese Journal of Clinical Oncology. 41:1101-1111
Objective: The actual condition of drug utilization and the adverse drug reactions profile of irinotecan hydrochloride hydrate (irinotecan), an antitumor drug, were examined on the basis of all the case survey results from April 1995 to January 2000.
Autor:
Nagahiro Saijo, Hideo Kunitoh, Koji Takeda, Yukito Ichinose, Nobuyuki Yamamoto, Hiroshi Sakai, Masahiro Fukuoka, Yutaka Ariyoshi, Kazuhiko Nakagawa, Kaoru Kubota
Publikováno v:
Journal of Thoracic Oncology. 5:702-706
Introduction To determine the dose-limiting toxicity and recommended dose (RD) of cisplatin (CDDP) combined with S-1 (tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) for patients with non-small cell lung cancer and to evaluate effica
Autor:
Toshikazu Saito, Hirokazu Watanabe, Kazuhiko Nakagawa, R. Morinaga, Yoshikazu Hasegawa, Yutaka Ariyoshi, Taroh Satoh, Toru Kakihara, Noriyuki Masuda, Asuka Tsuya, Tetsuo Taguchi, M. Terashima, Shinya Ueda, Yumiko Aoyama, Masaki Miyazaki, Masahiro Fukuoka, Yohko Hashimoto, Isamu Okamoto
Publikováno v:
Clinical Cancer Research. 15:3872-3880
Purpose: YM155, a novel molecular targeted agent, suppresses survivin, a member of the inhibitor of apoptosis protein family that is overexpressed in many tumor types. The aim of this study was to determine the maximum tolerated dose (MTD) and to ass
Autor:
Masahiro Fukuoka, Yutaka Nishiwaki, Kazuhiko Nakagawa, Tomohide Tamura, Yuichiro Ohe, Kaoru Kubota, Yasuo Ohashi, S. Negoro, Yutaka Ariyoshi, Nagahiro Saijo
Publikováno v:
Annals of Oncology. 18:317-323
Background To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell lung cancer (NSCLC) by a non-inferiority design. Patients and metho
Autor:
Masahiro Fukuoka, Nobuyuki Yamamoto, Takashi Seto, Koji Takeda, Yutaka Ariyoshi, Masahiko Ando, Kenji Tamura, I. Okamoto
Publikováno v:
Journal of Clinical Oncology. 24:2549-2556
Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence and risk factors remain largely unknown. We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of th
Autor:
Masahiro Fukuoka, Hisanobu Niitani, Nobuyuki Katakami, Yasuo Ohashi, T. Sugiura, S. Negoro, N Masuda, Yutaka Ariyoshi, Y. Takada, S. Kudoh
Publikováno v:
British Journal of Cancer
To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and
Autor:
Y. Kurita, Nagahiro Saijo, Kaoru Kubota, K. Furuse, Yutaka Ariyoshi, H. Ikegami, Tomohide Tamura, Masahiro Fukuoka
Publikováno v:
Annals of Oncology. 11:445-450
Summary Background Although chemoradiotherapy is standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC), few long-term survival data exist. Patients and methods Between October 1989 and December 1991, 74 patients with histol
Autor:
Motokazu Suyama, Masaki Kuwabara, Makoto Ogawa, M. Nishio, Susumu Suzuki, Shunzo Hatooka, Tetsuya Mitsudomi, Takashi Takahashi, Masayuki Shinoda, Yutaka Ariyoshi, Toshitada Takahashi, Yasushi Yatabe, Kunihiko Gotoh
Publikováno v:
Scopus-Elsevier
Background: The presence of autoantibodies to p53 protein has been associated with the presence of p53 (also known as TP53) gene mutations in primary tumors and with poor prognosis. This study was undertaken to deter,1 mine the clinical significance
Autor:
S. Kudoh, Yutaka Ariyoshi, H Yamamoto, Kiyoyuki Furuse, A Kinoshita, Masahiro Fukuoka, Y. Fujiwara, Y. Takada
Publikováno v:
Journal of Clinical Oncology. 16:1068-1074
PURPOSE Irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC) as monotherapy. Cisplatin is also a key drug against SCLC. We conducted a phase II study of CPT-11 combined with cisplatin to evaluate the efficacy and toxicity of this re
Autor:
Yutaka Ariyoshi, Tetsuya Mitsudomi, Makoto Ogawa, Hidehiko Saito, Kaoru Shimokata, Ryuzo Ueda
Publikováno v:
Cancer Chemotherapy and Pharmacology. 58:1-3